Muriel Poublanc

Dexamethasone as a probe for docetaxel clearance

Florent Puisset, Étienne Chatelut, Florence Dalenc et al. · Cancer Chemotherapy and Pharmacology · 2004 · 62 citations

Pharmacy, Pharmacokinetics, Pharmacology +9

αvβ3 Integrin and Fibroblast growth factor receptor 1 (FGFR1): Prognostic factors in a phase I–II clinical trial associating continuous administration of Tipifarnib with radiotherapy for patients with newly diagnosed glioblastoma

Anne Ducassou, Emmanuelle Uro‐Coste, Pierre Verrelle et al. · European Journal of Cancer · 2013 · 55 citations

Medicine, Oncology, Pharmacology +17

Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging

Anne Laprie, S. Ken, Thomas Filleron et al. · BMC Cancer · 2019 · 53 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Cystatin C as a New Covariate to Predict Renal Elimination of Drugs

Fabienne Thomas, Sophie S ronie-Vivien, Laurence Gladieff et al. · Clinical Pharmacokinetics · 2005 · 52 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +16

Phase I Trial of Tipifarnib (R115777) Concurrent With Radiotherapy in Patients with Glioblastoma Multiforme

Elizabeth Cohen‐Jonathan Moyal, Anne Laprie, M. Delannes et al. · International Journal of Radiation Oncology*Biology*Physics · 2007 · 44 citations

Medicine, Oncology, Radiation Oncology +12